updated 3/29/2011 7:15:41 AM ET 2011-03-29T11:15:41

DALLAS, March 29, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Novogen Ltd. (ADR) (Nasdaq:NVGN). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/lp/NVGN

Novogen Ltd. (NVGN) is an Australia-based biotechnology company engaged in pharmaceutical research and development, as well as marketing of consumer healthcare products. The Company is primarily involved in the development of prescription drugs based on the isoflavonoid technology platform. The Company is structured into four divisions: Pharmaceutical division, which develops a portfolio of prescription drugs; Consumer Health division, which develops a range of non-prescription products; Marshall Edwards Inc., which focuses on the development of oncology drugs, and Glycotex Inc., which focuses on seeking funds to enable to complete and extend the clinical development program. Within its divisions the Company also conducts oncology program, cardiovascular program, dermatological program and anti-inflammatory program.

This newsletter has been helping traders make great investment decisions on OBCI; click here for a 25% discount offer.

In the report, the analyst notes:

"Shares of NVGN set a new 52-week high of $2.97 Monday, before settling the day at $2.17, an increase of 104.72% for the day. About 5.40 million shares changed hands during the session, well above the stock's 10-day average volume of 102.47K. NVGN is currently trading above its 50-day moving average of $0.83 and 200-day moving average of $0.65. Market capitalization currently stands at $44.79 million and it has 20.64 million outstanding shares."

"NVGN's subsidiary Marshall Edwards Inc. (MSHL) last week announced the publication of results from a phase II clinical trial of intravenous phenoxodiol in combination with cisplatin in women with platinum-resistant ovarian cancer. The publication is now available on the International Journal of Gynecological Cancer Web site and scheduled to print in the May issue of the journal."

To read the entire report visit: www.microstockprofit.com/lp/NVGN

See what investors are saying about NVGN at http://www.stockhideout.com

Get breaking news on NVGN at http://thestockmarketwatch.com/

MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com

MicroStockProfit.com Disclosure

MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.

CONTACT: Brian Johnson

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com